Bernhard Resch1, Beatrice Egger2, Stefan Kurath-Koller3, Berndt Urlesberger4. 1. Division of Neonatology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Austria; Research Unit for Neonatal Infectious Diseases and Epidemiology, Medical University of Graz, Austria. Electronic address: Bernhard.resch@medunigraz.at. 2. Research Unit for Neonatal Infectious Diseases and Epidemiology, Medical University of Graz, Austria. 3. Division of Neonatology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Austria; Research Unit for Neonatal Infectious Diseases and Epidemiology, Medical University of Graz, Austria. 4. Division of Neonatology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Austria.
Abstract
OBJECTIVE: To obtain data on respiratory syncytial virus (RSV) associated hospitalization rates in preterm infants of 28 weeks gestational age and less in the era of palivizumab prophylaxis. METHODS: Retrospective single-center cohort study including all preterm infants up to 28 weeks+6days gestational age and born between 2004 and 2012 at a tertiary care university hospital. Data on RSV related hospitalizations over the first two years of life covering at least two RSV seasons (November-April) were analyzed. RESULTS: Ninety-one of 287 (32%) infants were hospitalized due to respiratory illness, and a total of 17 infants (5.9%) tested RSV positive during the first 2 years of life. Fourteen infants (4.9%) were hospitalized during the first RSV season. RSV hospitalization rate in infants with BPD was 4.5% (2/44) compared to 4.9% (12/243) without BPD. Palivizumab prophylaxis was documented in 74.6% of the infants. Infants with RSV compared to other respiratory tract infection were of younger age (6.8 vs. 9.1 months; p=0.049), had longer hospital stays (median 11 vs. 5 days; p=0.043) and more severe respiratory illness (median LRI score 3 vs. 2; p=0.043). CONCLUSIONS: Despite palivizumab prophylaxis the burden of RSV disease and all cause respiratory illness was still remarkable in this vulnerable preterm population and mainly limited to the first season.
OBJECTIVE: To obtain data on respiratory syncytial virus (RSV) associated hospitalization rates in preterm infants of 28 weeks gestational age and less in the era of palivizumab prophylaxis. METHODS: Retrospective single-center cohort study including all preterm infants up to 28 weeks+6days gestational age and born between 2004 and 2012 at a tertiary care university hospital. Data on RSV related hospitalizations over the first two years of life covering at least two RSV seasons (November-April) were analyzed. RESULTS: Ninety-one of 287 (32%) infants were hospitalized due to respiratory illness, and a total of 17 infants (5.9%) tested RSV positive during the first 2 years of life. Fourteen infants (4.9%) were hospitalized during the first RSV season. RSV hospitalization rate in infants with BPD was 4.5% (2/44) compared to 4.9% (12/243) without BPD. Palivizumab prophylaxis was documented in 74.6% of the infants. Infants with RSV compared to other respiratory tract infection were of younger age (6.8 vs. 9.1 months; p=0.049), had longer hospital stays (median 11 vs. 5 days; p=0.043) and more severe respiratory illness (median LRI score 3 vs. 2; p=0.043). CONCLUSIONS: Despite palivizumab prophylaxis the burden of RSV disease and all cause respiratory illness was still remarkable in this vulnerable preterm population and mainly limited to the first season.
Authors: Daniela Benítez-Guerra; Cecilia Piña-Flores; Miguel Zamora-López; Francisco Escalante-Padrón; Victoria Lima-Rogel; Ana María González-Ortiz; Marcela Guevara-Tovar; Sofía Bernal-Silva; Beatriz Benito-Cruz; Fernanda Castillo-Martínez; Luz E Martínez-Rodríguez; Vianney Ramírez-Ojeda; Nallely Tello-Martínez; Rodrigo Lomelí-Valdez; Jack Salto-Quintana; Sandra Cadena-Mota; Daniel E Noyola Journal: Influenza Other Respir Viruses Date: 2020-01-09 Impact factor: 4.380